Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB2 | P07550 | 1/20 | 0.50 |
| ▸ | PDE2A | O00408 | 1/20 | 0.41 |
| ▸ | CA12 | O43570 | 1/20 | 0.40 |
| ▸ | CA1 | P00915 | 1/20 | 0.40 |
| ▸ | CA2 | P00918 | 1/20 | 0.40 |
| ▸ | CA4 | P22748 | 1/20 | 0.40 |
| ▸ | CA9 | Q16790 | 1/20 | 0.40 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.40 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.33 |
| ▸ | ROCK2 | O75116 | 2/20 | 0.33 |
| ▸ | ROCK1 | Q13464 | 2/20 | 0.33 |
| ▸ | CIT | O14578 | 1/20 | 0.31 |
| ▸ | GABRP | O00591 | 1/20 | 0.31 |
| ▸ | GABRD | O14764 | 1/20 | 0.31 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.31 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.31 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.31 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.31 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22954544 | 1.00 | ADRB2 (0.50) | ADRB2PDE2ACA12CA1CA2 | |
| SCHEMBL24017079 | 0.80 | DPP4 (0.43) | CA12CA1CA2CA4CA9 | |
| SCHEMBL2010094 | 0.80 | DPP4 (0.43) | CA12CA1CA2CA4CA9 | |
| SCHEMBL24017078 | 0.80 | DPP4 (0.43) | CA12CA1CA2CA4CA9 | |
| SCHEMBL28321091 | 0.80 | ESR1 (0.46) | CA12CA1CA2CA4CA9 | |
| SCHEMBL624888 | 0.80 | PYCR1 (0.42) | CA12CA1CA2CA4CA9 | |
| SCHEMBL27207789 | 0.80 | ADRB2 (0.54) | ADRB2PDE2A | |
| SCHEMBL30885664 | 0.80 | ADRB2 (0.54) | ADRB2PDE2A | |
| SCHEMBL1314596 | 0.79 | ADRB2 (0.72) | ADRB2PDE2AROCK2ROCK1CIT | |
| SCHEMBL319930 | 0.76 | ADRB2 (0.50) | ADRB2PDE2ACA12CA2CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250197387-A1 | BCL-XL DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2025-06-19 | — | — | US | disclosed |
| EP-1966156-B1 | NEW COMPOUNDS III | ASTRAZENECA AB (SE) | 2011-12-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250197387-A1 | BCL-XL DEGRADERS AND USES THEREOF | XIAP, BCL2L1, BCL2L10 | ADRB2 4868/4885PDE2A 4738/4885CA12 3826/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.